next generation sequencing based foundationone liquid cdx Search Results


next-generation sequencing panel genoptix aml molecular profile  (Genoptix Inc)
90
Genoptix Inc next-generation sequencing panel genoptix aml molecular profile
Next Generation Sequencing Panel Genoptix Aml Molecular Profile, supplied by Genoptix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/next+generation+sequencing+panel+genoptix+aml+molecular+profile/pm38649367-283-13-21
Average 90 stars, based on 1 article reviews
next-generation sequencing panel genoptix aml molecular profile - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone cdx  (Foundation Medicine Inc)
99
Foundation Medicine Inc foundationone cdx
Foundationone Cdx, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/FoundationOne+CDx/pm38606821-74-8-10
Average 99 stars, based on 1 article reviews
foundationone cdx - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
foundationone liquid cdx ngs  (Foundation Medicine Inc)
97
Foundation Medicine Inc foundationone liquid cdx ngs
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Liquid Cdx Ngs, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/FoundationOne+Liquid+CDx/pmc09941792-39-9-13
Average 97 stars, based on 1 article reviews
foundationone liquid cdx ngs - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
genoptix 5-gene panel  (Genoptix Inc)
90
Genoptix Inc genoptix 5-gene panel
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Genoptix 5 Gene Panel, supplied by Genoptix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/5+gene+panel/10__1038_slash_labinvest__2015__15-3203-15-17
Average 90 stars, based on 1 article reviews
genoptix 5-gene panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone heme panel  (Foundation Medicine Inc)
95
Foundation Medicine Inc foundationone heme panel
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Heme Panel, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/FoundationOne+Heme/pmc07387311-125-14-17
Average 95 stars, based on 1 article reviews
foundationone heme panel - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
foundationone cdx sophia genetics  (Sophia Genetics)
97
Sophia Genetics foundationone cdx sophia genetics
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Cdx Sophia Genetics, supplied by Sophia Genetics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/Blood+cancers/10__1016_slash_j__dscb__2024__100126-69-31-33
Average 97 stars, based on 1 article reviews
foundationone cdx sophia genetics - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
carboxyphenol ba  (Chem Impex International)
95
Chem Impex International carboxyphenol ba
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Carboxyphenol Ba, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/Salicylic+acid/pm33543929-33-0-5
Average 95 stars, based on 1 article reviews
carboxyphenol ba - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
myeloid molecular profile  (Genoptix Inc)
90
Genoptix Inc myeloid molecular profile
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Myeloid Molecular Profile, supplied by Genoptix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/myeloid+molecular+profile/pm38299605-43-11-13
Average 90 stars, based on 1 article reviews
myeloid molecular profile - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ngs assays raindance  (RainDance Technologies)
90
RainDance Technologies ngs assays raindance
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Ngs Assays Raindance, supplied by RainDance Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/ngs+assays+raindance/pmc06290101-142-19-21
Average 90 stars, based on 1 article reviews
ngs assays raindance - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone liquid cdx  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare foundationone liquid cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Liquid Cdx, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/foundationone+liquid+cdx/10__1200_slash_po__24__00254-28-34-46
Average 90 stars, based on 1 article reviews
foundationone liquid cdx - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
koselugo (selumetinib  (AstraZeneca ltd)
90
AstraZeneca ltd koselugo (selumetinib
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Koselugo (Selumetinib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/selumetinib+koselugo/pm32760021-13-184-192
Average 90 stars, based on 1 article reviews
koselugo (selumetinib - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone assay  (Neoplus inc)
90
Neoplus inc foundationone assay
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Assay, supplied by Neoplus inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+foundationone+liquid+cdx/foundationone+assay/pm32119917-241-8-13
Average 90 stars, based on 1 article reviews
foundationone assay - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The FoundationOne liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.

Journal: Case Reports in Oncology

Article Title: Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report

doi: 10.1159/000526642

Figure Lengend Snippet: a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The FoundationOne liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.

Article Snippet: After another 4 years and multiple therapies, she underwent FoundationOne®Liquid CDx NGS testing (Foundation Medicine, Cambridge, MA, USA, https://www.foundationmedicine.com/ ), which identified PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations (Fig. ).

Techniques: Mutagenesis

a A FoundationOne®Liquid CDx testing that was collected via blood draw on Patient 2. PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations were found (Collection date December 19, 2018). b A FoundationOne®CDx testing from a tissue bone biopsy that was performed after academic center consultation. PTEN I101N, ESR1 Y537N, CDH1 F810fs, and PIK3CA E545K mutations, TMB-4Mut/Mb, and Microsatellite-stable were reported (collection date: January 21, 2019).

Journal: Case Reports in Oncology

Article Title: Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report

doi: 10.1159/000526642

Figure Lengend Snippet: a A FoundationOne®Liquid CDx testing that was collected via blood draw on Patient 2. PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations were found (Collection date December 19, 2018). b A FoundationOne®CDx testing from a tissue bone biopsy that was performed after academic center consultation. PTEN I101N, ESR1 Y537N, CDH1 F810fs, and PIK3CA E545K mutations, TMB-4Mut/Mb, and Microsatellite-stable were reported (collection date: January 21, 2019).

Article Snippet: After another 4 years and multiple therapies, she underwent FoundationOne®Liquid CDx NGS testing (Foundation Medicine, Cambridge, MA, USA, https://www.foundationmedicine.com/ ), which identified PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations (Fig. ).

Techniques: